Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 8 |
| List of Tables | 7 | 3 |
| List of Figures | 10 | 2 |
| Neurodegenerative Disease Market to 2017 - Introduction | 12 | 2 |
| GBI Research Report Guidance | 13 | 1 |
| Neurodegenerative Disease Market to 2017 - Global Market Overview | 14 | 7 |
| Introduction | 14 | 2 |
| Revenue | 16 | 1 |
| Generic Share | 17 | 1 |
| Annual Cost of Treatment | 18 | 1 |
| Treatment Usage Patterns | 19 | 1 |
| Diseased Population | 20 | 1 |
| Treatment Seeking Population | 20 | 1 |
| Diagnosis Population | 20 | 1 |
| Prescription Population | 20 | 1 |
| Neurodegenerative Disease Market to 2017 - Geographical Landscape | 21 | 14 |
| The US | 23 | 1 |
| Revenue | 23 | 1 |
| Annual Cost of Treatment | 24 | 1 |
| Treatment Usage Patterns | 25 | 1 |
| Diseased Population | 26 | 1 |
| Treatment Seeking Population | 26 | 1 |
| Diagnosis Population | 26 | 1 |
| Prescription Population | 26 | 1 |
| Top Five Countries of Europe | 27 | 1 |
| Revenue | 27 | 1 |
| Annual Cost of Treatment | 28 | 1 |
| Treatment Usage Patterns | 29 | 1 |
| Diseased Population | 30 | 1 |
| Treatment Seeking Population | 30 | 1 |
| Diagnosis Population | 30 | 1 |
| Prescription Population | 30 | 1 |
| Japan | 31 | 1 |
| Revenue | 31 | 1 |
| Annual Cost of Treatment | 32 | 1 |
| Treatment Usage Patterns | 33 | 1 |
| Diseased Population | 34 | 1 |
| Treatment Seeking Population | 34 | 1 |
| Diagnosis Population | 34 | 1 |
| Prescription Population | 34 | 1 |
| Neurodegenerative Disease Market to 2017 - Therapeutic Landscape | 35 | 61 |
| Introduction | 35 | 2 |
| Revenue | 37 | 2 |
| Revenue by Country | 39 | 2 |
| Generic Share | 41 | 1 |
| Annual Cost of Treatment | 42 | 1 |
| Treatment Usage Patterns | 43 | 1 |
| Diseased Population | 44 | 1 |
| Treatment Seeking Population | 44 | 1 |
| Diagnosis Population | 44 | 1 |
| Prescription Population | 44 | 1 |
| Geriatric Population and Increased Life Expectancy | 45 | 1 |
| Expected Launch of New Drugs Will Drive the Alzheimer s Disease Therapeutics Market in Future | 45 | 1 |
| Low Diagnosis Rate Reduces Number of Patients on AD Drug Therapy | 46 | 1 |
| Slower Drug Development Programs and Recent Drug Failures Will Hamper the Development of Promising Molecules | 46 | 1 |
| Multiple Sclerosis Market | 46 | 1 |
| Introduction | 46 | 2 |
| Revenue | 48 | 2 |
| Revenue by Country | 50 | 1 |
| Generic Share | 51 | 1 |
| Annual Cost of Treatment | 52 | 1 |
| Treatment Usage Patterns | 53 | 1 |
| Diseased Population | 54 | 1 |
| Treatment Seeking Population | 54 | 1 |
| Diagnosis Population | 54 | 1 |
| Prescription Population | 54 | 1 |
| Drivers and Restraints to Multiple Sclerosis Market | 55 | 1 |
| Drivers for Multiple Sclerosis Market | 55 | 1 |
| Launch of Several High-priced Novel Disease-modifying Therapies | 55 | 1 |
| Increased Prescription Population | 55 | 1 |
| Restraints for Multiple Sclerosis Market | 56 | 1 |
| Patient Affordability and Reimbursement Issue | 56 | 1 |
| Patent Expiry of Major Drugs Is Expected to Cause Market Decline | 56 | 1 |
| Parkinson s Disease Therapeutics Market | 57 | 1 |
| Introduction | 57 | 1 |
| Revenue | 57 | 2 |
| Revenue by Country | 59 | 2 |
| Generic Share | 61 | 1 |
| Annual Cost of Treatment | 62 | 1 |
| Treatment Usage Patterns | 63 | 1 |
| Diseased Population | 64 | 1 |
| Treatment Seeking Population | 64 | 1 |
| Diagnosis Population | 64 | 1 |
| Prescription Population | 64 | 1 |
| Drivers and Restraints to Parkinson s Disease Therapeutics Market | 65 | 1 |
| Drivers for the Parkinson s Disease Therapeutics Market | 65 | 1 |
| Rise in Geriatric Population and Increase in Life Expectancy | 65 | 1 |
| Restraints for the Parkinson s Disease Therapeutics Market | 65 | 1 |
| Lack of Definite Diagnostic Techniques Delays Treatments of PD | 65 | 1 |
| Patent Expiry in Upcoming Years Will Affect the Market Growth | 65 | 1 |
| Diabetic Neuropathy Market | 66 | 1 |
| Introduction | 66 | 1 |
| Revenue | 67 | 1 |
| Revenue by Country | 68 | 2 |
| Generic Share | 70 | 1 |
| Annual Cost of Treatment | 71 | 1 |
| Treatment Usage Pattern | 72 | 1 |
| Diseased Population | 73 | 1 |
| Treatment Seeking Population | 73 | 1 |
| Diagnosis Population | 73 | 1 |
| Prescription Population | 73 | 1 |
| Drivers and Restraints to Diabetic Neuropathy Therapeutics Market | 74 | 1 |
| Drivers for Diabetic Neuropathy Market | 74 | 1 |
| Expected Launch of New Molecules Will Drive the Diabetic Neuropathy Therapeutics Market Growth in Future | 74 | 1 |
| Increasing Diseased Population | 74 | 1 |
| Restraints for the Diabetic Neuropathy Therapeutics Market | 74 | 1 |
| Patent Expiry | 74 | 1 |
| Huntington s Disease Market | 75 | 1 |
| Introduction | 75 | 1 |
| Revenue | 75 | 2 |
| Revenue by Country | 77 | 2 |
| Generic Share | 79 | 1 |
| Annual Cost of Treatment | 80 | 1 |
| Treatment Usage Pattern | 81 | 1 |
| Diseased Population | 82 | 1 |
| Treatment Seeking Population | 82 | 1 |
| Diagnosis Population | 82 | 1 |
| Prescription Population | 82 | 1 |
| Drivers and Restraints to the Market for Huntington s Disease | 83 | 1 |
| Drivers for Huntington s disease | 83 | 1 |
| Expected Launch of Promising and High Priced Molecules Will Drive HD Market In Future | 83 | 1 |
| Restraints for Huntington s Disease | 84 | 1 |
| Low Treatment Seeking Rate | 84 | 1 |
| Absence of Curative Therapy and Affordability Issue of Medicines | 84 | 1 |
| Introduction | 85 | 2 |
| Revenue | 87 | 1 |
| Revenue by Country | 88 | 2 |
| Generic Share | 90 | 1 |
| Annual Cost of Treatment | 91 | 1 |
| Treatment Usage Patterns | 92 | 1 |
| Diseased Population | 93 | 1 |
| Treatment Seeking Population | 93 | 1 |
| Diagnosis Population | 93 | 1 |
| Prescription Population | 93 | 1 |
| Drivers and Restraints to Amyotrophic Lateral Sclerosis Market | 94 | 1 |
| Drivers for Amyotrophic Lateral Sclerosis Market | 94 | 1 |
| Expected Launch of Promising Pipeline Molecules Will Drive the Growth of ALS Market In Future | 94 | 1 |
| Rise in Geriatric Population May Increase Burden of ALS Patient In Future | 94 | 1 |
| The Rise in Awareness among the ALS Patients May Drive the ALS Market | 94 | 1 |
| High Unmet Needs and Orphan Drug Status to New Molecules Meant To Treat ALS | 95 | 1 |
| Restraints for Amyotrophic Lateral Sclerosis Market | 95 | 1 |
| Low Diagnosis Rate | 95 | 1 |
| Patent Expiry of Rilutek | 95 | 1 |
| Neurodegenerative Disease Market to 2017 - Product Pipeline Analysis | 96 | 25 |
| Introduction | 96 | 1 |
| Introduction | 97 | 10 |
| Diabetic Neuropathy | 107 | 1 |
| Introduction | 107 | 1 |
| Multiple Sclerosis | 108 | 1 |
| Introduction | 108 | 4 |
| Introduction | 112 | 5 |
| ALS | 117 | 1 |
| Introduction | 117 | 2 |
| Huntington s disease | 119 | 1 |
| Introduction | 119 | 2 |
| Neurodegenerative Disease Market to 2017 - Competitive Landscape | 121 | 8 |
| Market Share Analysis | 121 | 1 |
| Teva | 122 | 1 |
| Company Overview | 122 | 1 |
| SWOT Analysis | 122 | 1 |
| Biogen Idec | 123 | 1 |
| Company Overview | 123 | 1 |
| SWOT Analysis | 123 | 1 |
| Merck Serono | 124 | 1 |
| Company Overview | 124 | 1 |
| SWOT Analysis | 124 | 1 |
| Bayer Schering Pharma AG | 125 | 1 |
| Company Overview | 125 | 1 |
| SWOT Analysis | 125 | 1 |
| Novartis | 126 | 1 |
| Company Overview | 126 | 1 |
| SWOT Analysis | 126 | 1 |
| Boehringer Ingelheim | 127 | 1 |
| Company Overview | 127 | 1 |
| SWOT Analysis | 127 | 1 |
| Pfizer | 128 | 1 |
| Company Overview | 128 | 1 |
| SWOT Analysis | 128 | 1 |
| Neurodegenerative Disease Market to 2017 - M&A Landscape | 129 | 12 |
| M&A Deals (2009-2010) | 129 | 2 |
| M&A Deals by Region | 131 | 1 |
| M&A Deals by Value | 132 | 1 |
| Deal Summary of Top 10 M&A Deals by Value | 133 | 1 |
| Abbott Laboratories Acquires Solvay Pharmaceuticals | 133 | 1 |
| Biovail Completes Merger with Valeant Pharmaceuticals | 133 | 1 |
| Dainippon Sumitomo Pharma Completes Acquisition of Sepracor for $2.6 Billion | 133 | 1 |
| Lundbeck Acquires Ovation Pharmaceuticals | 133 | 1 |
| Eli Lilly and Company Acquires Avid Radiopharmaceuticals | 134 | 1 |
| Biogen Idec Acquires Panima Pharmaceuticals | 134 | 1 |
| H. Lundbeck Acquires Life Health | 134 | 1 |
| Endo Pharmaceuticals Completes Acquisition of Penwest Pharmaceutical | 135 | 1 |
| UCB Acquires Remaining Stake in Schwarz Pharma | 135 | 1 |
| Lexicon Pharmaceuticals Completes Acquisition of Symphony Icon | 135 | 1 |
| Licensing Deals | 136 | 1 |
| Deal Summary | 137 | 1 |
| Cephalon Enters Into Licensing Agreement with Mesobla | 137 | 1 |
| Synosia Therapeutics Enters Into Licensing Agreement with UCB for SYN-115 and SYN-118 | 137 | 1 |
| Genzyme Acquires Rights of Campath from Bayer HealthCare | 137 | 1 |
| Biogen Idec Enters Into an Agreement with Acorda Therapeutics | 138 | 1 |
| Biovail Enters Into Licensing Agreement with ACADIA Pharmaceuticals | 138 | 1 |
| Biogen Idec Enters Into Licensing Agreement with Knopp Neurosciences for KNS-760704 | 138 | 1 |
| Merck Serono Enters Into Licensing Agreement with Apitope Technology | 139 | 1 |
| GlaxoSmithKline Enters Into Licensing Agreement with Impax Pharmaceuticals for IPX066 | 139 | 1 |
| Santhera Pharmaceuticals Enters Into Licensing Agreement with Ipsen for Fipamezole | 139 | 1 |
| Biovail Laboratories International Enters Into Licensing Agreement with Kyowa Hakko Kirin | 139 | 1 |
| Addex Pharmaceuticals Extends Collaboration Agreement With Merck &Co. | 140 | 1 |
| Neurodegenerative Disease Market to 2017 - Appendix | 141 | 8 |
| Market Definitions | 141 | 1 |
| Abbreviations | 141 | 1 |
| Research Methodology | 142 | 6 |
| Coverage | 142 | 1 |
| Secondary Research | 143 | 1 |
| Primary Research | 143 | 1 |
| Therapeutic Landscape | 144 | 1 |
| Epidemiology-based Forecasting | 144 | 2 |
| Market Size by Geography | 146 | 1 |
| Geographical Landscape | 147 | 1 |
| Pipeline Analysis | 147 | 1 |
| Competitive Landscape | 147 | 1 |
| Expert Panel Validation | 147 | 1 |
| Contact Us | 147 | 1 |
| Disclaimer | 147 | 1 |
| Sources | 148 | 1 |